Enamine’s Contribution to Antiviral Development
In a significant advancement in the fight against coronaviruses, the Ukrainian research and development firm Enamine has announced its pivotal role in the creation of a promising broad-spectrum antiviral drug, designated as ASAP-0017445. This initiative was part of an innovative open-science project, known as the COVID Moonshot, which collaborated with the AI-driven Structure-enabled Antiviral Platform (ASAP) consortium. This collaborative effort aims to expedite the discovery and development of antiviral medications capable of addressing potential future pandemics.
Enamine’s involvement has been integral, as it provided more than 2,000 synthetic compounds during the initial phases of the program. These efforts culminated in the identification of ASAP-0017445, a drug candidate that is positioned to be a direct-to-generic treatment option. This approach aims to ensure global accessibility, a critical factor in pandemic preparedness.
Promising Pre-Clinical Findings
The pre-clinical candidate ASAP-0017445 has demonstrated encouraging preliminary results concerning safety and efficacy. It has been recognized and nominated by the Drugs for Neglected Diseases initiative (DNDi), a non-profit organization focused on addressing neglected diseases, as a potentially effective antiviral treatment for coronaviruses. This nomination underscores the scientific community’s optimism regarding the new candidate’s ability to combat future viral outbreaks.
The consortium behind this initiative formed during the COVID-19 pandemic, with the goal of accelerating the discovery of oral antiviral medications. Enamine’s contributions were vital in streamlining the compound development process, allowing for rapid production and analysis of new molecules. This efficiency was achieved through proximity testing of compounds and conducting essential Tier 1 ADME (Absorption, Distribution, Metabolism, and Excretion) tests.
Collaborative Success and Future Implications
The final optimization of the compounds developed by Enamine was carried out in collaboration with MedChemica, resulting in the refined candidate ASAP-0017445. According to Vladimir Ivanov, Executive Vice President of Enamine, the collaboration exemplified a significant global effort, bringing together researchers from around the world to enhance drug discovery processes aimed at strengthening pandemic resilience.
The structural details of ASAP-0017445 were made publicly available in March 2025, with the patent and all related data recently published to further support the open science initiative. The full spectrum of 2,000 compounds generated through this collaboration is now accessible in Enamine’s catalogue, facilitating further research and development in the field of antiviral therapies.
As the world continues to grapple with the implications of viral pandemics, the ongoing work of Enamine and its partners highlights the importance of innovative approaches in drug discovery, underscoring a commitment to global health and preparedness for future challenges.
Related
